TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stratum 1: Subjects must be undergoing a non-myeloablative stem cell transplant from a 6/6 matched, sibling donor for the treatment of a malignancy~* Stratum 2: Subjects must be undergoing a non-myeloablative stem cell transplant from a 3/6, 4/6, or 5/6 matched, sibling donor for the treatment of a malignancy.~* Stratum 3: Subjects must be undergoing a myeloablative stem cell transplant from a 3/6, 4/6, or 5/6 matched, sibling donor for the treatment of a malignancy.~* Donor must be CMV sero-positive.~* Karnofsky performance status ≥ 70%.~* Subject and donor must be one of the following HLA types: HLA A\*0201, HLA-A\*0101, HLA-A\*2402, HLA-B\*0702, HLA-B\*0801, HLA-B\*35, HLA-DR\*1, or HLA-DR\*4.~* Availability of the stem cell donor to provide multiple PBMC samples for T-cell culture if needed. These samples could be obtained via a 90cc peripheral blood draw or through leukapheresis. Stem cell donor must satisfy BMT Program criteria for undergoing leukapheresis to provide DLI and consent to provide repeat leukapheresis if this is necessary.~* Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.~* Ability to return to Duke University Medical Center for adequate follow-up as required by this protocol.~* In order to receive their T cell infusions, subjects should be:~* At least 2 weeks from the time of their allogeneic stem cell transplant.~* Without Grade 3 or 4, non-hematologic, major organ toxicity within the preceding 1 week; all non major organ toxicities must have resolved to grade-2 or less.~Exclusion Criteria:~* Pregnant women and nursing mothers.~* Current or prior history of brain metastases.~* More than 12 months since their allogeneic stem cell re-infusion.~* HIV+, Hepatitis BsAg+, Hepatitis C Ab+

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sodium Nitroprusside in Early Course Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Having a DSM-V diagnosis of Schizophrenia or schizoaffective disorder with \<5 years from the onset of psychosis~* Having up to 2 years of lifetime exposure to antipsychotics~* Having total score of \>65 on the Positive and Negative Syndrome Scale (PANSS) with a score of \>4 on 1 or more PANSS items (delusions, conceptual disorganization, hallucinatory behavior, suspiciousness, or unusual thought content)~* Having English proficiency~* Being competent and willing to give informed consent~Exclusion Criteria:~* Having substance dependence or abuse within the past 6 months~* Having history of retinal disease; myopia \>4.0 diopters; symptomatic orthostatic hypotension~* Any change of psychotropic medications within the previous 4 weeks~* Currently taking clozapine~* Having prior history of intolerance to Sodium Nitroprusside~* Having treatment with medications that may interfere with the metabolism or excretion or effects of Sodium Nitroprusside~* Being pregnancy/breast feeding~* Having unstable major medical (renal, hepatic, or cardiac) or neurologic illness~* Having significant inflammatory or immune conditions~* Having treatment with anti-inflammatory drugs, hormones or immunosuppressant agents in the 6 months before study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Sodium Nitroprusside Arm (Type: EXPERIMENTAL): Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours
- Placebo Arm (Type: PLACEBO_COMPARATOR): 5% Dextrose (0.5 μg/kg/min) for 4 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: First-Sight Refractive Error Correction: Direct Comparison to Autorefraction Results in Children 7 to 18 Years of Age

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subjects are between 7 to 18 years of age.~2. Healthy subjects~3. A refractive error of -4.50 to +4.50 diopter spherical error and astigmatism up to -1.50 diopters on manifest refraction and autorefraction as documented in their medical records.~4. Best corrected visual acuity (BCVA) of 20/20 with cycloplegic refraction.~5. No known ocular pathology from previous clinical exams that may limit best corrected visual acuity.~Exclusion Criteria:~1. Refractive error greater than -4.50 or +4.50 diopter, or astigmatism greater than -1.50 diopters.~2. Known ocular (corneal, lenticular, vitreal, or retinal) pathology that may limit BCVA.~3. Best corrected visual acuity with spectacles of 20/25 or worse.~4. Any previous surgical or laser procedures that may limit BCVA~5. Narrow angles of the eyes~6. Adults, 19 years or older

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tetra-NIRS Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The selection of subjects enrolled for testing must meet the following criteria:~  * Subjects must be 18 years of age or older.~ * Subjects are patients of one of the institutions and are currently scheduled for UDS~ * Male subjects must have LUTS~ * Female subjects must have OAB~ * Subjects must give their informed consent prior to enrolment.~Exclusion Criteria:~* The patient has an existing health condition which the investigators feel will not allow for safe or accurate measurements with the Tetra-NIRS device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Urodynamics + Tetra (Type: EXPERIMENTAL): All patients were recruited to the same arm and receive Urodynamics testing as part of the routine diagnostic work-up, plus the Tetra-NIRS intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Interest of EMDR Schizophrenic Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years and over,~* Hospitalized for decompensated psychotic disorder, Positive diagnosis of schizophrenia or schizoaffective disorder (according to the DSM-V psychiatry manual),~* With positive or negative symptoms according to the Positive and Negative Syndrome Scale (PANSS),~* Stabilized clinical condition (considered compatible with hospital discharge),~* With ambulatory follow-up planned after hospitalization~Exclusion Criteria:~* \< 18 years,~* Patients who do not meet the diagnostic criteria (according to the DSM-V psychiatry manual) for schizophrenic or schizoaffective disorder),~* Non-French speaking or illiterate patients,~* Cognitive disorders making it impossible the understanding and the none- opposition to the study,~* Non-stabilized clinical condition (incompatible with hospital discharge),

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: None): Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
- EMDR group (Type: None): Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Hysterectomy vs Supracervical Hysterectomy at the Time of Sacrocolpopexy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18, who are to undergo laparoscopic sacrocolpopexy for uterovaginal prolapse and desire concurrent hysterectomy at the time of surgery~* Other concomitant laparoscopic or prolapse and anti-incontinence procedures (cystocele repair, rectocele repair or mid-urethral sling procedures) will be performed at the primary surgeon's discretion.~* Patient's must have an up-to-date PAP smear on record, or a PAP smear is performed in the office and verified to be normal pre-enrollment~Exclusion Criteria:~* Inability to comprehend written and/or spoken English~* Inability to provide informed consent~* Medical illness precluding laparoscopy~* Need for concomitant surgeries not related to pelvic organ prolapse or incontinence~* Sacrocolpoperineopexy~* Patients desiring uterine preservation (hysteropexy)~* Previous apical prolapse surgery (hysteropexy)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Laparoscopic supracervical hysterectomy (Type: ACTIVE_COMPARATOR): Minimally invasive procedure to remove a woman's uterus
- Vaginal hysterectomy (Type: EXPERIMENTAL): Surgical procedure to remove the uterus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Study of IgG Fc Glycan Composition in Human Immunity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female 18-80 years of age~* Healthy volunteers without significant medical problems~* Able to give informed consent to participate~* Willing to receive a single dose of an FDA-approved vaccine (either the influenza virus, pneumococcal or meningococcal vaccine)~* Documented previous infection with dengue, zika or chikungunya virus or no history of dengue, zika or chikungunya infection.~Exclusion Criteria:~* Prior allergic reaction to commercial vaccination~* For Flumist participants: Close contact with person with severely compromised immune system requiring isolation~* For Flumist participants: Current illness that limits delivery to nasal airway (mild illness, such as diarrhea or mild respiratory infection with or without fever, and local infections do not apply)~* History of seizure disorder for Flumist group participants only.~* Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study.~* Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation.~* In the opinion of the investigator, the volunteer is unlikely to comply with the study protocol.~* Currently taking systemic steroids or other immunomodulatory medications including anticancer medications and antiviral medications.~* Egg allergy~* Received the influenza vaccine less than 1 month ago and/or received the pneumococcal and meningococcal vaccine less than 4 years ago~* Confirmed HIV infection, positive for hepatitis B surface antigen or positive for hepatitis C antibodies.~* Is pregnant or lactating~* History of Guillain-Barre syndrome~* Poor venous access~* Unable to continue participation for 12 weeks~* Any clinically significant abnormality on medical history or physical examination including history of immunodeficiency or autoimmune disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Biologic/Vaccine, Age 18-64 cohort (Type: ACTIVE_COMPARATOR): Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
- Biologic/Vaccine, Age 65-80 cohort (Type: ACTIVE_COMPARATOR): Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
- Vaccine, healthy adults (Type: ACTIVE_COMPARATOR): Vaccination. IM Pneumococcal, meningococcal, or flu vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of relapsed or refractory advanced leukemias or MDS~* ECOG 0-2~* Adequate renal function~* Adequate liver function~* ≥ 2 weeks from prior chemotherapy, radiation therapy or major surgery~* ≥ 4 weeks from other investigational anticancer therapy~* Agree to practice effective contraception~Exclusion Criteria:~* Known CNS involvement by leukemia~* Currently receiving radiotherapy, biological therapy, or any other investigational agents~* Uncontrolled intercurrent illness~* Pregnant or lactating~* Known to be HIV-positive~* Known active hepatitis B and/ or hepatitis C infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CYC140 single agent (Type: EXPERIMENTAL): CYC140 will be administered as a single agent on Day 1 and Day 8 of each 3 week cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. All participants will be between 30-90 years old, inclusive, clinically characterized as having AD, having FTD, or being cognitively normal controls (NC).~2. All subjects must be willing and able to undergo testing procedures.~3. Cholinesterase inhibitors and memantine - symptomatic drugs approved for AD - will be allowed since these drugs are not expected to significantly affect amyloid load.~General inclusion criteria are shown below:~1. Normal subjects: Healthy individuals aged to match AD and FTD groups, who are non-depressed, non-demented, and without a complaint of memory loss. A brief neuropsychological test, the 3MS-R or Modified Mini-Mental State Examination, Revised (Tschanz et al., 2002), will be given to confirm that the subject is not cognitively impaired.~2. FTD subjects: Patients seen in the University of Utah (UU) Cognitive Disorders Clinic (CDC) who have been clinically characterized and meet Neary criteria for frontotemporal dementia (Neary et al., 1998).~3. AD subjects: Patients seen in the UU CDC who have been clinically characterized to meet NINCDS-ADRDA criteria for probable AD (McKhann et al., 1984). These criteria were established in 1984 for diagnosis of AD by the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders Association (ADRDA).~Exclusion Criteria:~1. Subjects with medical conditions that have a high risk of associated cognitive symptoms such as transient ischemic attack (TIA), stroke, seizures, or head injury with loss of consciousness within five years~2. Subjects with Axis I psychiatric diagnoses other than treated depression~3. Subjects who are not medically stable will be excluded from the study. Examples of medically unstable patients include uncontrolled hypertension, heart/liver/renal failure, and other conditions requiring acute medical attention~4. Subjects cannot have a serum glucose level greater than 180 mg/dl for FDG-PET imaging~5. Subjects who are too claustrophobic to undergo FDG-PET or 11C PIB-PET imaging~6. Subjects who require conscious sedation or anesthesia to undergo FDG-PET or 11C PIB-PET imaging~7. Subjects who are unable to follow instructions to urinate after completing scanning procedures

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed relapsed and advanced chronic lymphocytic leukemia (CLL)~  * Binet stage B or C disease with rapid disease progression, enlarged lymph nodes and organs, or severe B-symptoms~* No prior non-response to fludarabine combination therapy~PATIENT CHARACTERISTICS:~* ECOG performance status 0-3~* Life expectancy \> 6 months~* No severe organ dysfunction~* No other prior or concurrent neoplasm, autoimmune hemolytic anemia, or thrombocytopenia~PRIOR CONCURRENT THERAPY:~* No more than three previous treatment regimens for CLL (fludarabine allowed)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- FCM (Type: ACTIVE_COMPARATOR): Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) q28d, max. 6 cycles
- FCM + G-CSF (Type: EXPERIMENTAL): Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) Filgrastim (G-CSF) s.c. (5 µg/kg/d beginning on day +6 until neutrophil recovery above 1500/µl.) q28d, max. 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Comparison of Revolve™ and AuraGen 123 With AuraClens™ in Autologous Fat Grafting to the Breast

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients \> 18 years and \< 65 years of age~* Patients undergoing an aesthetic fat grafting procedure to the breast (breast augmentation) without a breast implant.~* Patients must be able to provide written informed consent, understand and be willing to comply with study-related procedures and follow-up visits.~* Patients must be non-smokers.~* Patients with available/adequate harvest sites for fat grafting.~* Anticipated harvested fat volume between 400 and 1400 cc~* Anticipated fat injection volume 150-350 cc per breast~* Patients must agree to maintain their weight (i.e. within 5%) by not making any major changes in their diet or lifestyle during the study.~Exclusion Criteria:~* Skin rash in the treatment area.~* Patients who smoke or use nicotine products.~* Patients with bleeding disorders or currently taking anticoagulants.~* Patients with a history of trauma or surgery to the treatment area.~* Patients with a history of breast cancer.~* Active, chronic, or recurrent infection.~* Compromised immune system (e.g. diabetes).~* Hypersensitivity to analgesic agents.~* Co-morbid conditions that could limit their ability to participate in the study or to comply with follow-up requirements.~* Untreated drug and/or alcohol abuse.~* Pregnant or breastfeeding.~* Any issue that, at the discretion of the investigator, would contraindicate the patient's participation.~* Patients who do not wish to have the study area (breast) photographed~NOTE Please note that there is no remuneration for participation in this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Fat grafting with the AuraGen 1-2-3 with AuraClens System (Type: ACTIVE_COMPARATOR): Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the AuraGen 1-2-3 with AuraClens system.
- Fat grafting with the Revolve System (Type: ACTIVE_COMPARATOR): Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the Revolve System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients from 3 months to 10 years of age.~* Patients diagnosed of dermatomycoses produced by yeasts or dermatophytes by KOH technique at the inclusion moment, which has to be confirmed by culture.~* Obtention of the informed consent of the parents or legal representatives of the patients~Exclusion Criteria:~* Previous treatment with oral or topical antifungal drugs.~* Hypersensitivity to ciclopirox olamine or some of the cream excipients.~* Use of topical or oral steroids concomitantly.~* Patients with mycoses on the scalp or nails.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- ciclopirox (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues